Anatara Lifesciences Ltd (ANR.AX)
AUD 0.01
(0.0%)
AUD 0.01
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -1.45 Million AUD | 55.58% |
| 2023 | -3.28 Million AUD | -8.69% |
| 2022 | -3.02 Million AUD | 2.91% |
| 2021 | -3.11 Million AUD | 25.99% |
| 2020 | -4.2 Million AUD | -39.7% |
| 2019 | -3.01 Million AUD | 20.55% |
| 2018 | -3.78 Million AUD | -97.08% |
| 2017 | -1.92 Million AUD | -91.13% |
| 2016 | -1 Million AUD | 44.02% |
| 2015 | -1.79 Million AUD | -105.29% |
| 2014 | -875.29 Thousand AUD | -369.76% |
| 2013 | -186.32 Thousand AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 FY | -2.1 Million AUD | 35.98% |
| 2024 Q4 | -776.23 Thousand AUD | 0.0% |
| 2024 Q2 | -955.64 Thousand AUD | 0.0% |
| 2023 FY | -3.28 Million AUD | -8.69% |
| 2023 Q4 | -1.93 Million AUD | 0.0% |
| 2023 Q2 | -1.35 Million AUD | 0.0% |
| 2022 Q2 | -1.51 Million AUD | 0.0% |
| 2022 FY | -3.02 Million AUD | 2.91% |
| 2022 Q4 | -1.5 Million AUD | 0.0% |
| 2021 Q4 | -1.39 Million AUD | 0.0% |
| 2021 Q2 | -1.71 Million AUD | 0.0% |
| 2021 FY | -3.11 Million AUD | 25.99% |
| 2020 Q2 | -2.25 Million AUD | 0.0% |
| 2020 FY | -4.2 Million AUD | -39.7% |
| 2020 Q4 | -1.95 Million AUD | 0.0% |
| 2019 FY | -3.01 Million AUD | 20.55% |
| 2019 Q4 | -1.33 Million AUD | 0.0% |
| 2019 Q2 | -2.09 Million AUD | 0.0% |
| 2018 FY | -3.78 Million AUD | -97.08% |
| 2018 Q4 | -2 Million AUD | 0.0% |
| 2018 Q2 | -1.78 Million AUD | 0.0% |
| 2017 Q2 | -513.09 Thousand AUD | 0.0% |
| 2017 FY | -1.92 Million AUD | -91.13% |
| 2017 Q4 | -1.4 Million AUD | 0.0% |
| 2016 Q2 | -1.28 Million AUD | 0.0% |
| 2016 FY | -1 Million AUD | 44.02% |
| 2016 Q4 | 279.02 Thousand AUD | 0.0% |
| 2015 Q2 | -823.97 Thousand AUD | 0.0% |
| 2015 FY | -1.79 Million AUD | -105.29% |
| 2015 Q4 | -972.93 Thousand AUD | 0.0% |
| 2014 Q3 | - AUD | 100.0% |
| 2014 Q2 | -123.54 Thousand AUD | 0.0% |
| 2014 FY | -875.29 Thousand AUD | -369.76% |
| 2014 Q4 | -751.75 Thousand AUD | 0.0% |
| 2013 FY | -186.32 Thousand AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AdAlta Limited | -5.26 Million AUD | 72.268% |
| Acrux Limited | -9.83 Million AUD | 85.162% |
| Amplia Therapeutics Limited | -4.42 Million AUD | 67.025% |
| Biome Australia Limited | -1.91 Million AUD | 23.735% |
| BTC Health Limited | 1.05 Million AUD | 238.268% |
| Chimeric Therapeutics Limited | -12.3 Million AUD | 88.147% |
| CSL Limited | 5.64 Billion AUD | 100.026% |
| Clarity Pharmaceuticals Ltd | -44.8 Million AUD | 96.743% |
| Clinuvel Pharmaceuticals Limited | 49.14 Million AUD | 102.969% |
| Noxopharm Limited | -7.53 Million AUD | 80.635% |
| PharmAust Limited | -6.65 Million AUD | 78.087% |
| Proteomics International Laboratories Limited | -7.23 Million AUD | 79.823% |
| Prescient Therapeutics Limited | -7.18 Million AUD | 79.696% |
| PYC Therapeutics Limited | -38.85 Million AUD | 96.245% |
| Race Oncology Limited | -13.38 Million AUD | 89.095% |
| Starpharma Holdings Limited | -15.15 Million AUD | 90.375% |
| EZZ Life Science Holdings Limited | 9.71 Million AUD | 115.017% |
| Botanix Pharmaceuticals Limited | -14.69 Million AUD | 90.074% |
| Memphasys Limited | -2.7 Million AUD | 46.038% |
| Nyrada Inc. | -4.56 Million AUD | 68.004% |
| Telix Pharmaceuticals Limited | - AUD | Infinity% |
| Bio-Gene Technology Limited | -3.06 Million AUD | 52.354% |
| Zelira Therapeutics Limited | -5.93 Million AUD | 75.428% |
| Patrys Limited | -3.53 Million AUD | 58.772% |
| Dimerix Limited | -25.05 Million AUD | 94.177% |
| Neuren Pharmaceuticals Limited | 225.96 Million AUD | 100.646% |
| Orthocell Limited | -11.68 Million AUD | 87.509% |
| Imugene Limited | -140.93 Million AUD | 98.965% |
| Cynata Therapeutics Limited | -8.8 Million AUD | 83.434% |
| Immutep Limited | -44.93 Million AUD | 96.753% |
| Arovella Therapeutics Limited | -7.19 Million AUD | 79.715% |
| Alterity Therapeutics Limited | -19.6 Million AUD | 92.556% |
| Nanollose Limited | -1.24 Million AUD | -16.747% |
| Invex Therapeutics Ltd | -2.13 Million AUD | 31.613% |
| NeuroScientific Biopharmaceuticals Limited | -2.05 Million AUD | 29.05% |
| Island Pharmaceuticals Limited | -2.87 Million AUD | 49.226% |
| Biotron Limited | -5.15 Million AUD | 71.674% |
| Radiopharm Theranostics Limited | -47.2 Million AUD | 96.909% |
| Tissue Repair Ltd | -4.87 Million AUD | 70.075% |
| AnteoTech Limited | -11.72 Million AUD | 87.557% |
| Hexima Limited | -1 Million AUD | -44.647% |
| Paradigm Biopharmaceuticals Limited | -65.11 Million AUD | 97.759% |
| Recce Pharmaceuticals Ltd | -22.05 Million AUD | 93.383% |
| Avecho Biotechnology Limited | -4.58 Million AUD | 68.205% |
| Actinogen Medical Limited | -12.83 Million AUD | 88.635% |
| Immuron Limited | -5.8 Million AUD | 74.847% |
| Argenica Therapeutics Limited | -5.67 Million AUD | 74.271% |